US Department of Justice releases strategy memo to address Rx opioid and heroin epidemic

27 September 2016
seal-of-the-united-states-department-of-justice-big

As part of the US Obama Administration’s commitment to address the rising public health challenges caused by the national prescription opioids and heroin epidemic, Attorney General Loretta Lynch issued a memo this week announcing the department’s three-part prevention, enforcement and treatment strategy.

The memo lays out action items, institutionalizes best practices, and builds on existing efforts by US Attorney’s Offices, the Drug Enforcement Administration and other Department of Justice components.

Additionally, Attorney General Lynch sent a letter to Governors calling on them to strengthen the effectiveness of Prescription Drug Monitoring Programs (PDMPs) and to improve data sharing of vital information from doctors and pharmacists about patient prescriptions - both within states and among neighboring states.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical